| abstract |
Disclosed are compounds of Formula 1, n n n n n n n n n n and pharmaceutically acceptable salts thereof, wherein L, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , and R 7 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating obesity and related diseases, disorders, and conditions associated with MetAP2. |